Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patientsAdriano Gravina, Federica Perrone, Saverio Cinieri et al.|ESMO Open|2025Cited by 8
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approachesSara Parola, C. De Angelis, Vincenzo Di Lauro et al.|Annals of Oncology|2022Cited by 1
Taxane-based adjuvant therapy for early breast cancer (EBC): A meta-analysis of the predictive effect of ER and HER2 status.Michelino De Laurentiis, Sabino De Placido, Carmen Criscitiello et al.|Journal of Clinical Oncology|2010Cited by 0